Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

Author's Avatar
Dec 15, 2022

Topline results of the 12-month primary efficacy endpoint anticipated in January 2023